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Oral Immunotherapy in IgE-Mediated Cow’s Milk Protein Allergy 
 
Jody Bauer PA-S 
 
Statement of the Problem 
 Increasing prevalence of cow’s milk allergy in children 
 ONLY treatment option is strict avoidance 
 Accidental exposures resulting in life threatening reactions 
Research Questions 
 Does giving increasing doses of cow’s milk (OIT) improve tolerance to 
exposure to cow’s milk protein? Yes. Oral immunotherapy and SLIT 
improved CM tolerance in children with CMA determined by Skripak et al. 
(2008), Keet et al. (2012), Kim et al. (2011), Nadeau et al. (2011), and 
Levy et al. (2014). Researchers compared techniques of desensitization 
(OIT, SLIT, heated CM) and  methods of adverse reaction reduction 
(heated CM, anti-IgE pharmaceuticals).  
 Are there methods to maintain long-term tolerance to cow’s milk 
allergy? Currently, no medications or therapy plans have produced lifelong 
tolerance without maintenance therapy. Keet et al. (2012), Kim et al. 
(2011), Salmivesi et al. (2013), and Pajno (2013) researched approaches to 
maintain a high CM threshold and therefore long-term CM tolerance. 
Approaches to sustain desensitization through maintenance therapy (daily 
vs twice weekly) are required.  A decline in CM threshold occurs in 
participants previously desensitized without maintenance therapy Skripak 
et al. (2008). 
 Are there adjunctive therapies used with oral immunotherapy to 
decrease the frequency and severity of adverse reactions due to 
therapy? Five studies have reviewed the impact of adverse reactions in the 
development of OIT for CMA: Skripak et al. (2008), Keet et al. (2012), 
Kim et al. (2011), Nadeau et al. (2011) and Lucendo et al. (2014).  
Researchers noticed an increase in adverse reactions with OIT. Skripak et 
al. (2014) observed a statistically significant increase between OIT and 
placebo (p = .02).  Adverse multisystem reactions occurred more frequently 
in those receiving OIT compared to placebo or SLIT (Keet et al., 2012). 




Cow’s milk allergy prevalence in children has been increasing significantly 
over the last several decades. The diagnosis of a cow’s milk allergy (CMA) 
can occur through several methods such as signs and symptoms, double blind 
oral food challenge, skin prick testing, IgE and IgG4 serum levels. Currently, 
there are no treatments beyond strict allergen avoidance. The patient’s quality 
of life is impacted with the fear of inadvertent exposure resulting in allergic 
reactions that may be life threatening. Recent studies have explored 
desensitization to CM using oral immunotherapy (OIT), subcutaneous 
immunotherapy, and sublingual immunotherapy (SLIT). Research has found 
that desensitization will decrease the risk of allergic response to accidental 
exposures with the hope of lifelong tolerance to CM. The findings indicate 
means of successful desensitization, lifelong tolerance through maintenance 
regimens, and methods of increasing safety during desensitization. 
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Applicability to Clinical 
Practice 
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Pathophysiology 
The human body has 3 mechanisms of self defense: 
1. Barriers  
2. Inflammatory Response 
3. Adaptive (Acquired) Immunity 
Cow’s Milk Allergy Facts 
 2-7.5% of children <1 year of age have CMA  (Ludman et al., 2013) 
 2 % of adults in developed countries  have CMA (Sackeyfio et al., 2011) 
 39% of children with food allergies will have  a severe reaction once every 
four years (Umetsu, 2014) 
 125,000 emergency room visits yearly (Levy et al., 2014) 
 15,000 food induced anaphylaxis episodes yearly (Levy et al., 2014) 
 Economic impact is estimated at 25 billion dollars per year in the United 
States (Umetsu, 2014) 
 Physical and Psychological burden 
 53-57% of children outgrow CMA by 5 years of age 
 CMA is more likely to persist in children with asthma  or allergic rhinitis 
(Ludman et al., 2013) 
 No cure, current treatment is strict avoidance of  cow’s milk 
Literature Review 
 Oral Immunotherapy vs Placebo. Skripak et al. (2008) performed a 23 
week RCT in 20 children ages 6-21 with IgE-mediated Cow’s Milk Allergy 
(CMA) to desensitize children. Participants were escalated to a dose of 500 
mg (15 mL of milk), the dose was maintained for 13 weeks followed by a 
Double Blind Placebo Controlled Food Challenge (DBPCFC). The increase 
CM threshold was statistically significant (p= .002) in the Oral 
Immunotherapy (OIT) group in addition to a 76% increase in IgG4 (p = 
.002). Adverse reactions were statistically significant (p=.02) with OIT 
group having more reactions. 
 Cow’s Milk Oral Immunotherapy vs. Sublingual Immunotherapy. Keet 
et al. (2012)  performed a 66 week study  in 30 children ages 6-11 with 
IgE-mediated CMA evaluating the safety and efficacy of sublingual 
immunotherapy versus oral immunotherapy.  OIT participants tolerated the 
8g CM challenge at T5 (p = .002) compared to the SLIT group.  Adverse 
reactions were not statistically significant between the SLIT vs OIT groups 
(p = .73), however multisystem reactions were (p = <.001) with increased 
incidence in the OIT group. SLIT was limited by the route of 
administration and a maximum dose of 7 mg compared to the OIT group 1-
2 g.  
 Heated Milk Used to Accelerate Tolerance. Kim et al. (2011) conducted a 
37 month study of 88 children ranging in age from 8-75 months old (6 ¼ 
years) and demonstrated accelerated heated CM tolerance and increased 
CM threshold in 74% of the study participants.  Researchers observed a 
significant difference (p= .04) between adverse reactions between baked 
milk-tolerant and baked-milk reactive during DBPCFC in the follow up 
period. 
 Anti-IgE Therapy (omalizumab) Plus Oral Immunotherapy. Nadeau et 
al. (2011) performed a phase I study in 11 children ages 7-17 with IgE-
mediated CMA to accelerate desensitization and decrease adverse reactions. 
Omalizumab was administered every 2-4 weeks for 9 weeks at which time 
cow’s milk was introduced with a desensitization goal of 1000 mg.  The 
dose of CM was escalated weekly over the next 7-11 weeks with a goal of 
7250 mg (220 mL milk). Adverse reactions were 1.6% of dose 
administrations.  This study was limited by size, not having a placebo 
group, phase I study, and length of study. 
 Predictors of OIT Success. Levy et al. (2014) explored oral 
immunotherapy to predict successful desensitization and increase the cow’s 
milk protein threshold.  Two hundred eighty participants with IgE-mediated 
CMA, ages 4-27 years (mean 7.5) over 10 months enrolled. Levels of CM 
specific IgE and IgG4 were followed. Researchers found participants that 
successfully reached a desensitization goal of 7.2 g of CM were shown to 
have higher levels of IgG4. 
 What Is the Maintenance Therapy to Maintain Tolerance.  Salmivesi et 
al. (2013) explored further if successfully desensitized CMA participants 
could maintain desensitization with daily maintenance therapy for 3 years. 
Researchers found 79% of CMS participants maintained significant 
desensitization. Pajno et al. (2013) studied daily vs twice weekly 
maintenance therapy in a 12 month study with 38 children ages 4-13 years 
with no statistical significance between dosing regimens (p= .08). 
Type Name of 
Reaction 
Rate of  
Developement 






Examples of Disorders 







Frequently Autoimmune thrombocytopenic purpura, Graves 






Neutrophils Yes Systemic lupus erythematosus 
IV Cell-mediated  Delayed None Lymphocytes 
Macrophages 
No Contact sensitivity to poison ivy and metals 
(jewelry) 
  Innate Immunity   
Characteristics Barriers Inflammatory Response Adaptive (Acquired) Immunity 
Level of 
defense 
First line of defense against infection 
and tissue injury 
Second line of defense; occurs as a 
response to tissue injury or infection 
Third line of defense; initiated when innate 




Constant Immediate response Delay between primary exposure to antigen 
and maximum response, immediate against 
secondary exposure to antigen 
Specificity Broadly specific Broadly specific Response is very specific toward “antigen” 
Cells Epithelial cells Mast cells, granulocytes (neutrophils, 
eosinophils, basophils), monocytes 
(macrophages), natural killer (NK) 
cells, platelets, endothelial cells 
T lymphocytes, B lymphocytes, 
macrophages, dendritic cells 
Memory No memory involved No memory involved Specific immunologic memory by T and B 
lymphocytes 
Peptides Defensin, cathelicidins, collectins, 
lactoferrin, bacterial toxins 
Complement, clotting factors, kinins Antibodies, complement 
Protection Protection includes anatomic barriers 
(i.e., skin and mucous membranes), 
cells and secretory molecules or 
cytokines (e.g., lysozymes, low pH of 
stomach and urine) and ciliary activity 
Protection includes vascular response, 
cellular components (e.g., mast cells, 
neutrophils, macrophages, secretory 
molecules or cytokines, and activation 
of plasma protein systems 
Protection includes activated T and B 
lymphocytes, cytokines, and antibodies 
Type IV cell-mediated hypersensitivity reactions are: 
 Initiated by haptens that react with normal self-proteins in the skin and 
remain contained to the point of contact at which a cell-mediated immune 
response occurs.   
 Cytotoxic T lymphocytes (Tc cells) or lymphokine-producing Th1 cells 
directly kill foreign or abnormal cells as well as activate other cells to assist.  
 Cow’s milk protein, Type IV cell mediated reaction, results in tissue 
destruction in the gastrointestinal tract and contact dermatitis. 
How is Cow’s Milk 
 Allergy Diagnosed? 
 Double-blind, placebo-controlled food challenge 
(DBPCFC)GOLD STANDARD 
 
 Reoccurrence of symptoms after ingestion of the 
suspected food and resolution of these symptoms 
when strict avoidance is maintained  
 
 Skin prick testing (SPT) with >3 mm wheal 
(Sensitive: 95% NPV, 50% PPV) 
 
 Serum food-specific IgE levels with Phadia 
ImmunoCAP assay (95% clinical reactions) 
 
Adaptive Immunity is critical to a Type I hypersensitivity 
response to cow’s milk by utilizing antibodies as memory 
cells which recognize the cow’s milk antigen as foreign, 
prompting an IgE-mediated reaction involving both 
antigens, antibodies, and ultimately mast cell degranulation. 
